Discounted Cash Flow (DCF) Analysis Unlevered

Protagenic Therapeutics, Inc. (PTIX)

$2.04

-0.04 (-1.92%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2.04 | undervalue

Operating Data

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2.04
Beta 0.195
Diluted Shares Outstanding 4.32
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 39.93%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.730
Total Debt 0.34
Total Equity 8.81
Total Capital 9.15
Debt Weighting 3.76
Equity Weighting 96.24
Wacc

Build Up Free Cash

Year
A/P
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -----0-----
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.05
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 0.13
Equity Value -
Shares Outstanding 4.32
Equity Value Per Share -